In humans uric acid (UA) is the end product of degradation of purines. The handling of UA by the renal system
is a complex process which is not fully understood. To date, several urate transporters in the renal proximal tubule have
been identified. Among them, urate transporter 1 (URAT1) and a glucose transporter 9 (GLUT9) are considered of greater
importance, as potential targets for treatment of hyperuricemia and the potential associated cardio-metabolic risk. Therefore,
the recognition of the metabolic pathway of UA and elucidation of occurrence of hyperuricemia may provide important
insights about the relationship between UA, pre-hypertension (preHT) and the metabolic syndrome (MetS). We also
review the available clinical studies in this field, including experimental studies dealing with the mechanisms of UA
transport via different transporters, as well as current treatment options for hyperuricemia in patients with MetS, preHT or
cardiovascular risk factors.
Keywords: Cardiovascular risk, metabolic syndrome, metabolism, pre-hypertension, uric acid.
Rights & PermissionsPrintExport